Letrofam

Letrozole, the active ingredient in Letrofam, is a aromatase inhibitor presented as a 2.5 mg tablet for oral use. It treats postmenopausal estrogen receptor‑positive breast cancer, including adjuvant and metastatic disease.

GNH USA supplies Letrofam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Letrofam, an aromatase inhibitor, is employed in the management of estrogen‑driven breast cancer. - Postmenopausal estrogen receptor‑positive breast cancer: Reduces tumor growth by lowering circulating estrogen levels. - Adjuvant treatment of breast cancer: Decreases risk of disease recurrence after surgery. - Metastatic breast cancer: Provides disease control in advanced hormone‑sensitive tumors.

Letrofam may cause a range of adverse reactions.

Common Side Effects: - Hot flashes: Sudden feeling of warmth, often with sweating. - Joint and muscle pain: Aching discomfort in limbs or back. - Fatigue: Persistent tiredness not relieved by rest. - Nausea: Mild to moderate upset stomach. - Headache: Pressure or throbbing pain in the head. - Increased cholesterol: Elevated blood lipid levels.

Serious or Rare Side Effects: - Severe liver injury: Jaundice, dark urine, abdominal pain. - Allergic reactions: Rash, itching, swelling, or difficulty breathing. - Pulmonary embolism: Sudden shortness of breath, chest pain. - Osteoporotic fractures: Bone weakening leading to breaks. - Severe hypertension: Markedly high blood pressure. - Deep vein thrombosis: Swelling and pain in a limb.

Patients should be monitored for safety considerations before and during therapy. - Bone health monitoring: Assess bone mineral density regularly because estrogen depletion can accelerate bone loss. - Lipid profile assessment: Check cholesterol levels periodically as they may rise. - Liver function tests: Perform baseline and periodic liver enzyme measurements. - Cardiovascular risk evaluation: Review blood pressure and cardiovascular history. - Pregnancy avoidance: Do not use in women who are pregnant or may become pregnant. - Store at ambient temperature: Keep below 25°C in the original container, protected from moisture and direct sunlight.

Letrofam can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Estrogen replacement therapy: Counteracts aromatase inhibition and may diminish therapeutic benefit. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): Can raise letrozole plasma levels, increasing risk of adverse effects.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluconazole): May modestly increase letrozole exposure. - Warfarin: Potential for altered anticoagulant effect; monitor INR. - Statins: Possible additive impact on liver enzymes; check hepatic function. - Antidepressants (SSRIs): May affect hormone metabolism; observe clinical response.